Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8� Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13
IR@IICB: CSIR-Indian Institute of Chemical Biology, KolkataView Archive Info
Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8� Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but
Not IL-4 or IL-13
Haldar, Arun Kumar
Dana, Syamal Kumar
Cancer Biology and Inflammatory Disorder Division
There is an acute dearth of therapeutic interventions against visceral leishmaniasis that is required to
restore an established defective cell-mediated immune response. Hence, formulation of effective immunotherapy
requires the use of dominant antigen(s) targeted to elicit a specific antiparasitic cellular immune response.
We implemented hybrid cell vaccination therapy in Leishmania donovani-infected BALB/c mice by electrofusing
dominant Leishmania antigen kinetoplastid membrane protein 11 (KMP-11)-transfected bone marrow-derived
macrophages from BALB/c mice with allogeneic bone marrow-derived dendritic cells from C57BL/6 mice.
Hybrid cell vaccine (HCV) cleared the splenic and hepatic parasite burden, eliciting KMP-11-specific major
histocompatibility complex class I-restricted CD8� cytotoxic T-lymphocyte (CTL) responses. Moreover, splenic
lymphocytes of HCV-treated mice not only showed the enhancement of gamma interferon but also marked an
elevated expression of the Th2 cytokines interleukin-4 (IL-4) and IL-13 at both transcriptional and translational
levels. On the other hand, IL-10 production from splenic T cells was markedly suppressed as a result
of HCV therapy. CD8� T-cell depletion completely abrogated HCV-mediated immunity and the anti-KMP-11
CTL response. Interestingly, CD8� T-cell depletion completely abrogated HCV-induced immunity, resulting in
a marked increase of IL-10 but not of IL-4 and IL-13. The present study reports the first implementation of
HCV immunotherapy in an infectious disease model, establishing strong antigen-specific CTL generation as a
correlate of HCV-mediated antileishmanial immunity that is reversed by in vivo CD8� T-cell depletion of
HCV-treated mice. Our findings might be extended to drug-nonresponsive visceral leishmaniasis patients, as
well as against multiple infectious diseases with pathogen-specific immunodominant antigens.
Basu, Rajatava and Bhaumik, Suniti and Haldar, Arun Kumar and Naskar, Kshudiram and De, Tripti and Dana, Syamal Kumar and Walden, Peter and Roy, Syamal (2007) Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8� Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13. Infection and Immunity, 75 (12). pp. 5956-5966.